Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online December 10, 2007
Diabetes 57:777-782, 2008
DOI: 10.2337/db07-0008
© 2008 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0008v1
57/3/777    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Y.
Right arrow Articles by Liu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Y.
Right arrow Articles by Liu, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Genetic Variation and Association Analyses of the Nuclear Respiratory Factor 1 (nRF1) Gene in Chinese Patients With Type 2 Diabetes

Yang Liu1, Nifang Niu1, Xilin Zhu1, Te Du1, Xin Wang1, Dongmei Chen1, Xiaopan Wu1, Harvest F. Gu2, and Ying Liu1

1 National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China
2 Rolf Luft Centre for Diabetes Research, Department of Molecular Medicine and Surgery, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

Address correspondence and reprint requests to Ying Liu, PhD, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, 5 Dongdan 3 Tiao, Beijing 100005, China. E-mail: liuyingpumc{at}yahoo.com

Abbreviations: HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; NRF1, nuclear respiratory factor 1; OHA, oral hypoglycemic agent; PGC, peroxisome proliferator–activated receptor {gamma} coactivator; PPAR{gamma}, peroxisome proliferator–activated receptor {gamma}; RFLP, restriction fragment–length polymorphism; SNP, single nucleotide polymorphism; UTR, untranslated region


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
OBJECTIVE—Nuclear respiratory factor 1 (NRF1) is a strong biological and positional candidate to contribute to type 2 diabetes susceptibility. This study aimed at evaluating associations between NRF1 genetic polymorphisms and development of type 2 diabetes.

RESEARCH DESIGN AND METHODS—Using a variation screening approach, 6 novel and 10 known single nucleotide polymorphisms (SNPs) in the NRF1 gene were identified. Nine SNPs were then selected using pairwise tagging with an r2 cutoff of 0.8 and/or minor allele frequency of >5% and genotyped in 596 type 2 diabetic patients and 431 nondiabetic subjects, all of whom were Han Chinese.

RESULTS—Two novel SNPs (–46127T>C and +98560A>G) were associated with type 2 diabetes (P = 0.018 and 0.036; for possession of minor allele, odds ratio [OR] 0.620 and 3.199, with dominant model and correction for multiple comparisons). In SNP rs1882094 (+141G>T), the nondiabetic control subjects carrying GG genotype had lower fasting plasma glucose levels than carriers with other genotypes (P = 0.0002). One common haplotype (H2) mainly composed of SNPs rs6969098 (–24833 A>G), rs1882094, and another novel variant (+97884G>A) was significantly associated with type 2 diabetes (P = 0.016, OR 0.706). Subjects with this haplotype had lower fasting triglyceride levels when compared with those with other haplotypes (P = 0.010).

CONCLUSIONS—The present study shows an association of SNPs in the NRF1 gene with type 2 diabetes in a Han Chinese population. NRF1 genetic polymorphisms may be a suspectibility factor for type 2 diabetes by conferring abnormalities in triglyceride metabolism. Further studies should replicate this finding using larger and racially diverse populations.

Type 2 diabetes (Online Mendelian Inheritance in Man database no. 125853) is a metabolic disorder characterized by pancreatic β-cell dysfunction and insulin resistance (1). Insulin resistance is associated with decreased mitochodrial oxidative phosphorylation (2,3), which may contribute to the pathogenesis of this complex disease. Oxidative phosphorylation in mitochchondria is due to the functional interplay of genes expressed from both mitochodrial and nuclear genomes (4,5) and is regulated by multiple nuclear respiratory proteins and ATP synthase in mitochondria (2). One of these nuclear respiratory proteins is nuclear respiratory factor 1 (NRF1), which coordinates with peroxisome proliferator–activated receptor {gamma} (PPAR{gamma}) coactivators 1{alpha} and β (PGC-1{alpha} and -1β) (6). Interestingly, NRF1 and PGC-1 downregulate genes associated with oxidative metabolism in skeletal muscles of patients with type 2 diabetes or insulin resistance (2,7).

Several independent lines of evidence suggest that NRF1 plays a role in the pathogenesis of type 2 diabetes. First, the NRF1 gene is located on chromosome 7q32, a susceptibility locus for type 2 diabetes and insulin resistance (8,9). Second, muscle-specific overexpression of human NRF1 gene in transgenic mice causes an increase in glucose transport capacity in skeletal muscle via upregulating GLUT4 (10). Third, NRF1 mRNA expression in skeletal muscle of type 2 diabetic patients is decreased and inversely correlated with fasting glucose levels (2). Taken together, these data indicate that NRF1 represents a strong biological and positional candidate for a susceptibility factor for type 2 diabetes.

Despite the evidence described above, data concerning the genetic association of NRF1 in type 2 diabetes is limited. Only one recent report suggests that three single nucleotide polymorphisms (SNPs), including g.–46350ins/delA, g.+141G>T (rs1882094), and g.+54529A>G, in the NRF1 gene are marginally associated with type 2 diabetes in a Korean population (11). The present study further evaluated the association between the NRF1 genetic polymorphisms and type 2 diabetes by performing variation screening of the NRF1 gene and then carrying out a genetic association study in type 2 diabetic patients from a Han Chinese population.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Subject enrollment.
A total of 1,027 unrelated subjects, including type 2 diabetic patients (n = 596) and nondiabetic control subjects (n = 431), were enrolled in the present study. All subjects were Han Chinese and randomly selected from four Top Grade hospitals in Beijing city and Hebei province, China. Nondiabetic control subjects were >45 years old, had normal fasting plasma glucose levels (5.0 ± 0.3 mmol/l), and had no relatives with type 2 diabetes. All type 2 diabetic patients were diagnosed according to the World Health Organization criteria (WHO 1998). Most of the patients had medication with oral hypoglycemic agents (OHAs; 30.9%), insulin alone (53.6%), or insulin in combination with OHA (13.3%), whereas a few patients (2.2%) received only diet therapy. Genomic DNA from the peripheral blood was extracted by using a salting-out protocol. Clinical characteristics of nondiabetic control subjects and type 2 diabetic patients are summarized in Table 1. The study was performed after obtaining the informed consent from all subjects and was approved by the local ethics committee.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Clinical characteristics of nondiabetic control subjects and type 2 diabetic patients

 
Variation screening.
The sequences of the putative promoter region, exon-intron boundaries, and all exons, including the 5'- and 3'-untranslated regions (UTRs) (~1 kb) of NRF1 gene were PCR amplified in 20 type 2 diabetic patients and 20 nondiabetic control subjects. Human NRF1 mRNA NM_005011.2 was used as the contig sequence for defining the variants identified. PCR products were then sequenced using an optimized direct sequencing analysis protocol (Dye Terminator Cycle Sequencing Ready Reaction kit; ABI model 377 genetic analyzer; Perkin-Elmer, Foster City, CA). Primer specifics and optimized PCR conditions are available upon request.

PCR–restriction fragment–length polymorphism genotyping.
Using tagging with an r2 cutoff of 0.8 and/or minor allele frequency (MAF) of >5% and our own sequencing data, 9 of 16 SNPs (6 novel and 10 known) in the NRF1 gene were selected for genotyping experiments with PCR–restriction fragment–length polymorphism (PCR-RFLP) technique. Negative controls (water blanks) were included in each plate. For genotyping quality control, the case and control subjects were distributed randomly across the plates. Successful genotype calls were >97%, and 20% of samples were randomly genotyped twice for duplication accuracy, which was calculated to be 99%. Description of PCR-RFLP genotyping experiments is available in supplemental Table 1, which is detailed in the online appendix (available at http://dx.doi.org/10.2337/db07-0008).

Statistics analysis.
Genotype distributions for all studied SNPs in nondiabetic control subjects were tested for Hardy-Weinberg equilibrium (HWE). The minor allele was too rare for most polymorphisms to give enough power. Therefore, additive and dominant models were used to detect the allelic association. In the additive model, odds ratio (OR) value was expressed per difference in number of minor alleles. In the dominant model, ORs were shown as heterozygotes and homozygotes with minor alleles compared with homozygotes with major alleles. ORs and 95% CIs corresponding to P values without adjustment for age, sex, and BMI were obtained using {chi}2 tests. Among nondiabetic control subjects, the association between genotypes and quantitative traits was tested using Kruskal-Wallis analysis for traits with non-normal distribution or, alternatively, ANOVA for normally distributed traits. Retrospective statistical powers were calculated using software PowerSampleSize (PS version 2.1.31, available at http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize).

All statistical analyses were performed using SPSS statistical package (version 10.0) and/or SAS statistical package (version 9.1.2). We obtained estimates of pairwise linkage disequilibrium values using DnaSP 4.0 software package (Universitat de Barcelona, Barcelona, Spain) and/or Haploview software (version 3.32). Haplotype blocks were determined according to the CI method using the criteria of Gabriel et al. (12). Haplotype estimation was carried out using PHASE program (version 2.1). Haplotype frequency was determined by means of the algorithms implemented in the PHASE program (13). A P value of <0.05 was considered to be statistically significant. Pc values were calculated for multiple testing using Bonferroni's inequality method (14) and defined as P values (single test) x number of tests.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
We performed systematic variation screening of the NRF1 gene in type 2 diabetic patients and nondiabetic control subjects (n = 20/group) and identified 16 SNPs (Fig. 1). Three novel SNPs were found, one (–46127T>C) in the 5' region and two (+97884G>A and +98560A>G) in the 3'-UTR of the gene. A silent substitution encoding 47Ser (+141G>T) in exon 2 was recorded in dbSNP (rs1882094). Additionally, 12 SNPs were found to be intronic: three novel (+51889G>A, +52989A>C, and +97617T>G) and nine recorded, including rs753947 (–44339G>A), rs6969098 (–24833A>G), rs6951103 (+14255G>T), rs11769146 (+51910G>A), rs4731617 (+52196T>C), rs7782640 (+54099A>G), rs1962038 (+54253C>G), rs2293629 (+60107T>C), and rs2896423 (+60387C>T).


Figure 1
View larger version (18K):
[in this window]
[in a new window]

  		FIG. 1. Location of the SNPs identified in the NRF1 gene. The coding exons are marked by closed blocks; 5'- and 3'-UTRs are marked by open blocks. The first nucleotide of the translation start site is denoted as nucleotide +1. The polymorphisms genotyped in the larger population were designated P1–P9, respectively.

 
By the pairwise linkage disequilibrium analyses, two linkage disequilibrium blocks in the NRF1 gene (r2 >0.8) were found that were constructed with SNPs rs753947-rs6969098 and rs11769146-rs1962038-rs2293629, respectively. Nine SNPs were selected for genotyping experiments: –46127T>C, –rs6969098, rs1882094, rs11769146, rs4731617, +52989A>C, rs2896423, +97884G>A, and +98560A>G. These nine genotyped SNPs were named P1–P9 for convenience in analyses and description. ID numbers of SNPs recorded in dbSNP are represented in Fig. 1 and Table 2.


View this table:
[in this window]
[in a new window]

  		TABLE 2 Association between the NRF1 genetic polymorphisms and type 2 diabetic patients

 
Genotype distributions of all studied SNPs P1–P9 in nondiabetic control subjects were in HWE (P > 0.05). We assessed the association of each SNP with type 2 diabetes using additive and dominant models (Table 2). Two novel SNPs, P1 (–46127T>C) and P9 (+98560A>G), were significantly associated with type 2 diabetes (P = 0.001, OR 0.620 [95% CI 0.462–0.832] and P = 0.002, 3.199 [1.466–6.981]; Pc = 0.018 and 0.036 with correction for multiple comparisons in dominant models, respectively). The associations of SNPs, including P2 (rs6969098), P3 (rs1882094), P5 (rs4731617), and P7 (rs2896423), with type 2 diabetes were also found to be significant when the P values were not corrected for multiple comparisons. Of these four SNPs, P2 and P7 were linked to a decreased susceptibility for type 2 diabetes using both additive (P = 0.008, 0.793 [0.666–0.945]; P = 0.033, 0.671 [0.460–0.978]) and dominant (P = 0.011, 0.682 [0.507–0.916]; P = 0.041, 0.667 [0.451–0.985]) models. However, P3 was associated with an increased susceptibility risk for type 2 diabetes when applying a dominant model (P = 0.016, 1.355 [1.057–1.738]), whereas P5 (rs4731617) showed a decreased risk of type 2 diabetes when testing with an additive model (P = 0.027, 0.778 [0.626–0.968]). No significant association of P4 (rs11769146), P6 (novel +52989A>C), and P8 (novel +97884G>A) with type 2 diabetes was found.

We further examined the degree of linkage disequilibrium of SNPs P1–P9 and performed a haplotype association analysis. Table 3 displays the estimates of pairwise linkage disequilibrium (r2 and D' value) of the studied SNPs in the NRF1 gene. P9 was excluded from further analyses of haplotypes because of its low MAF (~0.02). Four common haplotypes with >5% frequency accounted for 71.1% of the observed haplotypes in type 2 diabetic patients (Table 4). Interestingly, in these four common haplotypes, the alleles from SNPs P1-P4-P5-P6-P7 were the same. Therefore, these four common haplotypes were simply defined as A-G-G, G-G-G, G-T-G, and A-G-A, and the alleles were from SNPs P2, P3, and P8. Furthermore, the common haplotype H2 was found to be significantly associated with a decreased risk of type 2 diabetes (P = 0.004; Pc = 0.016, OR 0.706 [95% CI 0.557–0.895]).


View this table:
[in this window]
[in a new window]

  		TABLE 3 Pairwise linkage disequilibrium values for SNPs in the NRF1 gene

 

View this table:
[in this window]
[in a new window]

  		TABLE 4 Common haplotypes of SNPs in the NRF1 gene

 
To predict the association between haplotypes and phenotypes, we conducted the comparison analyses in nondiabetic control subjects, because most of type 2 diabetic patients included in the present study had medical treatments, which may affect the real parameters. We found that the carriers with GG genotype of SNP P3 had lower fasting plasma glucose levels than those with other genotypes (4.95 vs. 5.11, P = 0.0002, Pc = 0.001). Moreover, the subjects carrying haplotype H2 had lower fasting triglyceride levels when compared with the subjects with other haplotypes (1.43 vs. 1.61 mmol/l, P = 0.002, Pc = 0.010; Table 5). There were no strong associations between the diabetes-related phenotypes and other genotypes or haplotypes when adjusting for multiple comparisons (data not shown).


View this table:
[in this window]
[in a new window]

  		TABLE 5 Phenotypes according to genotypes/haplotypes in nondiabetic control subjects

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we identified 16 SNPs, including 6 novel variants, in the NRF1 gene and found that 2 of the novel SNPs, P1 (–46127T>C) and P9 (+98560A>G), were significantly associated with type 2 diabetes in a Han Chinese population. Additionally, we demonstrated that P3 (rs1882094), a synonymous polymorphism located at codon 47 of exon 2, was related to fasting plasma glucose levels in nondiabetic control subjects. In this SNP, the carriers with genotype GG had lower fasting plasma glucose levels compared with subjects carrying genotypes GT and TT. The common haplotype, H2, mainly composed of SNPs P2, P3, and P8, was associated with lower levels of fasting triglyceride.

Interestingly, SNPs P1 and P2 are located at the putative promoter region of the NRF1 gene, whereas P8 and P9 are at the 3'-UTR. The noncoding portion of genomes may have a crucial role in gene expression (15), whereas UTRs are involved in many posttranscriptional regulatory pathways related to mRNA localization, stability, and translation efficiency. Initiation of protein synthesis could be influenced by sequence elements in both 5'- and 3'-UTRs (16). Diabetic dyslipidemia is a common clinical feature of type 2 diabetes, and patients have high levels of fasting triglycerides and hypertriglyceridemia (17,18). In the present study, haplotype H2 revealed the decreased association with the fasting triglyceride levels in nondiabetic subjects. It suggests that NRF1 genetic polymorphisms may be involved in regulating dyslipidemia and may subsequently contribute to the development of type 2 diabetes.

Many factors may contribute to variable results of genetic association study, major ones being sample size and ethnic stratification. In the present study, the sample size was adequately powerful (>80%) to detect differences between case and control subjects because type I error probability for a two sided-test ({alpha}) was defined as 0.05 and the OR was estimated as 1.5. However, the sample size of this study may not have been sufficiently powerful to detect modest effects of the NRF1 genetic polymorphisms. Further studies should replicate this study using a larger cohort of Han Chinese or Caucasian subjects.

Recently, 13 SNPs were identified in the NRF1 gene and 6 of these were studied for genetic association in a Korean cohort (11). In the present study, we identified 16 SNPs of the NRF1 gene in a Han Chinese population. Of the 16 identified SNPs, g.+141G>T, g.+97884G>A, and g.+98560A>G were represented in both the Han Chinese and Korean populations, whereas the remaining 13 SNPs identified in the present study were not reported in the Korean study (11). The differences in the NRF1 genetic polymorphisms between these two populations may be due to population specificities and/or the different range of exon-intron boundaries and different number of samples for direct-sequencing. However, SNP rs1882094 (+141G>T, P3 in the present study) was included in both the Korean and the present studies. In the Korean study, this polymorphism, composed of a common haplotype with another SNP +54529A>G, was found to be loosely associated with type 2 diabetes (11). Data from the present study are not only consistent with the report from the Korean study but also provide evidence of a link between this polymorphism and fasting glucose levels in nondiabetic control subjects. Furthermore, we found that the haplotype H2 constructed by this and other SNPs are associated with fasting triglyceride levels.

Type 2 diabetes is a multifactorial disease that involves insulin resistance and impaired glucose-induced insulin release (1). In most patients, type 2 diabetes is caused by alterations of several genes, each of which has a partial and additive effect (19). PGC-1, NRF1, and PPAR{gamma} interact to influence the biogenesis and maintenance of normal function of mitochondria (2,6). To better understand the mechanisms of abnormal mitochondrial oxidative phosphorylation involved in the pathogenesis of type 2 diabetes, our further studies will involve a multiplex-gene analysis of NRF1, PGC-1, and PPAR{gamma} genes.

In conclusion, the present study provides evidence that SNPs in the NRF1 gene are associated with type 2 diabetes in a Han Chinese population. Our findings strengthen a previous genetic report from a Korean population and suggest that the susceptibility of the NRF1 genetic polymorphisms may be involved in abnormalities in triglyceride metabolism.


   ACKNOWLEDGMENTS
 
This study has received grants from Natural Sciences Foundation of China (no. 30170886), the Research Fund for the Doctoral Training Program from the Ministry of Education in China (no. 20020023008), the Science Fund for Creative Research Groups (no. 30421003), and the Grant for Collaborative Diabetes Research between China and Europe from European Foundation for the Study of Diabetes.

We thank all subjects for participating in this study and the clinical doctors from four Top Grade hospitals in Beijing and Hebei province, China, for their excellent collection of samples. We are also grateful to Prof. Dongfeng Gu and Prof. Zhenglai Wu for revision of the English language in the manuscript.


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on December 2007. DOI: 10.2337/db07-0008.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication January 3, 2007 and accepted in revised form November 21, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318–368, 1992[Abstract]
  2. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466–8471, 2003[Abstract/Free Full Text]
  3. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with T2D. N Engl J Med 350:664–671, 2004[Abstract/Free Full Text]
  4. Poyton RO, McEwen JE: Crosstalk between nuclear and mitochondrial genomes. Annu Rev Biochem 65:563–607, 1996[Medline]
  5. Richard C: Scarpulla: nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 1576:1–14, 2002[Medline]
  6. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124, 1999[Medline]
  7. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273, 2003[Medline]
  8. Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, Foroud T, Kobes S, Baier L, Burns DK, Almasy L, Blangero J, Garvey WT, Bennett PH, Knowler WC: An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet 63:1130–1138, 1998[Medline]
  9. Cheng LS, Davis RC, Raffel LJ, Xiang AH, Wang N, Quinones M, Wen PZ, Toscano E, Diaz J, Pressman S, Henderson PC, Azen SP, Hsueh WA, Buchanan TA, Rotter JI: Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive Hispanic families. Circulation 104:1255–1260, 2001[Abstract/Free Full Text]
  10. Baar K, Song Z, Semenkovich CF, Jones TE, Han DH, Nolte LA, Ojuka EO, Chen M, Holloszy JO: Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity. FASEB J 17:1666–1673, 2003[Abstract/Free Full Text]
  11. Cho YM, Shin HD, Park BL, Kim JH, Park KS, Kim SY, Lee HK: Association between polymorphisms in the nuclear respiratory factor 1 gene and T2D mellitus in the Korean population. Diabetologia 48:2033–2038, 2005[Medline]
  12. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 296:2225–2229, 2002[Abstract/Free Full Text]
  13. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989, 2001[Medline]
  14. Sankoh AJ, Huque MF, Dubey SD: Some comments on frequently used multiple endpoint adjustments methods in clinical trials. Stat Med 16:2529–2542, 1997[Medline]
  15. Wang GJ, Yang P, Xie HG: Gene variants in noncoding regions and their possible consequences. Pharmacogenomics 7:203–209, 2006[Medline]
  16. Conklin D, Jonassen I, Aasland R, Taylor WR: Association of nucleotide patterns with gene function classes: application to human 3' untranslated sequences. Bioinformatics 18:182–189, 2002[Abstract/Free Full Text]
  17. Syvanne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl. 1):SI20–SI 23, 1997
  18. Betteridge DJ: Diabetic dyslipidaemia. Eur J Clin Invest 29 (Suppl. 2):12–16, 1999
  19. Elbein SC: Perspective: the search for genes for T2D in the post-genome era. Endocrinology 143:2012–2018, 2002[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0008v1
57/3/777    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Y.
Right arrow Articles by Liu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Y.
Right arrow Articles by Liu, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum